Ipca and Oncobiologics Create Strategic Biosimilars Partnership

For development, manufacture and commercialization

Ipca Laboratories announced that the Company has entered into an alliance with Oncobiologics, Inc., USA for the development, manufacture and commercialization of biosimilar monoclonal antibody products.

The biologics covered under this alliance are among the most popular therapies in the world for immunology and oncology disease indications.

Powered by Capital Market - Live News